source
- Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancerOn May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongo…
- UCB commits $2 billion to Candid's T cell engager program for autoimmune diseasesUCB, a long standing European pharmaceutical company, announced a $2 billion investment in Candid, a biotech focused on T cell engager therapies aimed at autoimmune conditions. The deal reflects U…